CD44 and glioblastoma: We then investigated the relationship of CD44+ TAMs with patient prognosis and found that higher expression of signature genes of CD44+ TAMs was associated with a worse clinical outcome in similar cancer types from The Cancer Genome Atlas (TCGA), including brain lower-grade glioma (LGG) and glioblastoma (GBM) (Fig. 2d and Supplementary Fig. 3c).